Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tofacitinib - Pfizer

Next Previous
X
Search
Drug Profile

Tofacitinib - Pfizer

Alternative Names: Cp-690,550; CP-690550; Jaquinus; Tasocitinib; Tofacitinib citrate; Tofacitinib XR; Xeljanz; Xeljanz XR

Latest Information Update: 03 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pfizer
  • Developer Johns Hopkins University; Oregon Health & Science University; Pfizer; University of Michigan
  • Class 2 ring heterocyclic compounds; Amides; Anti-inflammatories; Antiasthmatics; Antineoplastics; Antipsoriatics; Antirheumatics; Eye disorder therapies; Irritable bowel syndrome therapies; Nitriles; Piperidines; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase 3 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Ankylosing spondylitis; Juvenile rheumatoid arthritis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase III Glioblastoma
  • Phase II COVID-19 pneumonia
  • Phase I/II Cutaneous lupus erythematosus; Diffuse scleroderma; Systemic lupus erythematosus
  • Preregistration Submission Withdrawal Plaque psoriasis
  • No development reported Dermatomyositis; Granuloma annulare; Pulmonary sarcoidosis; Sarcoidosis
  • Discontinued Asthma; Atopic dermatitis; Crohn's disease; Dry eyes; Irritable bowel syndrome; Renal transplant rejection

Most Recent Events

  • 27 Mar 2024 Pfizer completes a phase-III trial in Juvenile rheumatoid arthritis (In adolescents, In children) in Argentina, Belgium, Brazil, Canada, China, Costa Rica, Germany, Hungary, India, Israel, Italy, Mexico, Poland, Russian, Slovakia, South Africa, Spain, Turkey, Ukraine, USA and United Kingdom (PO, Tablet, Liquid), (NCT03000439)
  • 07 Dec 2023 Pfizer completes the phase III trial for Ulcerative-colitis in USA (PO) (NCT04505410)
  • 14 Oct 2023 Pooled safety data of Clostridium difficile infection in ulcerative colitis from phase II, phase III and phase IIIb/IV trials presented at the 31st United European Gastroenterology Week (UEGW-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top